Download PDF
Horm Metab Res 2019; 51(04): 220-229
DOI: 10.1055/a-0867-1333
Review
© Georg Thieme Verlag KG Stuttgart · New York

Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis

Pu-liang Yu   *
1   Key Laboratory of Metallurgical Equipment and Control Technology of Ministry of Education, Wuhan University of Science and Technology, Wuhan, China
,
Cheng Wang   *
2   Department of Cardiology, Huazhong University of Science and Technology, Wuhan, China
,
Wei Li
2   Department of Cardiology, Huazhong University of Science and Technology, Wuhan, China
,
Feng-Xiao Zhang
2   Department of Cardiology, Huazhong University of Science and Technology, Wuhan, China
› Author Affiliations
Further Information

Publication History

received 17 January 2019

accepted 27 February 2019

Publication Date:
25 April 2019 (online)

Also available at
   Permissions and Reprints

Abstract

High blood pressure is related with increased cerebrovascular accident. High visfatin / NAMPT(nicotinamide phosphoribosyltransferase) plasma levels may promote vascular inflammation and atherosclerotic plaque destabilization and have been evaluated as a marker for identifying stages of essential hypertension. However, its role in the pathogenesis of hypertension and cerebrovascular accident (CVA) is still uncertain. In order to review and meta-analyze observational studies investigating visfatin concentration and the risk for hypertension or CVA, a systematic search of PubMed, ovid EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) until December 07, 2016 was performed. After data extraction and quality assessment, a meta-analysis was performed using RevMan 5.3 and STATA 14.0. A total of 1693 adults from 8 studies for hypertension (974 with hypertension) and 1696 adults from 7 CVA studies (957 with CVA) were enrolled in the current meta-analysis. Cochran’s Q-statistic and I2 test were applied to estimate the heterogeneity of the studies. The fixed-effects were used to compute the weighted mean difference in visfatin levels. Plasma visfatin concentration was much higher in hypertension and CVA patients than in healthy individuals. These evidences suggested the association of hypertension and CVA with higher plasma visfatin level.

Key words

visfatin - adipokine - hypertension - cerebrovascular accident

* These authors contributed equally to this paper


Supplementary Material

 

  • References

  • 1 Bekaert M, Verhelst X, Geerts A. et al. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: A systematic review. Obes Rev 2016; 17: 68-80
    PubMedGoogle Scholar
  • 2 Sumner AE, Falkner B, Kushner H. et al. Relationship of leptin concentration to gender, menopause, age, diabetes, and fat mass in African Americans. Obes Res 1998; 6: 128-133
    CrossrefPubMedGoogle Scholar
  • 3 Berndt J, Kloting N, Kralisch S. et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916
    CrossrefPubMedGoogle Scholar
  • 4 Lovren F, Pan Y, Shukla PC. et al. Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: Translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 2009; 296: E1440-E1449
    CrossrefPubMedGoogle Scholar
  • 5 Kendal-Wright CE, Hubbard D, Bryant-Greenwood GD. Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis. Placenta 2008; 29: 255-265
    CrossrefPubMedGoogle Scholar
  • 6 Adya R, Tan BK, Punn A. et al. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365
    CrossrefPubMedGoogle Scholar
  • 7 Liang Z, Wu Y, Xu J. et al. Correlations of serum visfatin and metabolisms of glucose and lipid in women with gestational diabetes mellitus. J Diabetes Investig 2016; 7: 247-252
    CrossrefPubMedGoogle Scholar
  • 8 Chen MP, Chung FM, Chang DM. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
    CrossrefPubMedGoogle Scholar
  • 9 Choi KM, Lee JS, Kim EJ. et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J Endocrinol 2008; 158: 203-207
    CrossrefPubMedGoogle Scholar
  • 10 Axelsson J, Witasp A, Carrero JJ. et al. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis 2007; 49: 237-244
    CrossrefPubMedGoogle Scholar
  • 11 Sethi JK, Vidal-Puig A. Visfatin: The missing link between intra-abdominal obesity and diabetes?. Trends Mol Med 2005; 11: 344-347
    CrossrefPubMedGoogle Scholar
  • 12 Hognogi LD, Simiti LV. The cardiovascular impact of visfatin – An inflammation predictor biomarker in metabolic syndrome. Clujul Med 2016; 89: 322-326
    PubMedGoogle Scholar
  • 13 Hsu CP, Yamamoto T, Oka S, Sadoshima J. The function of nicotinamide phosphoribosyltransferase in the heart. DNA Repair 2014; 23: 64-68
    CrossrefPubMedGoogle Scholar
  • 14 Burgos ES. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr Med Chem 2011; 18: 1947-1961
    CrossrefPubMedGoogle Scholar
  • 15 Wang P, Du H, Zhang RY. et al. Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats. J Physiol Sci 2010; 60: 317-324
    CrossrefPubMedGoogle Scholar
  • 16 Lu LF, Yang SS, Wang CP. et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009; 18: 354-359
    CrossrefPubMedGoogle Scholar
  • 17 Ozal E, Sahin I, Bolat I. et al. Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy. Blood Press Monit 2017; 22: 137-142
    CrossrefPubMedGoogle Scholar
  • 18 Kim DH, Kim C, Ding EL. et al. Adiponectin levels and the risk of hypertension: A systematic review and meta-analysis. Hypertension 2013; 62: 27-32
    CrossrefPubMedGoogle Scholar
  • 19 Dogru T, Sonmez A, Tasci I. et al. Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension. J Hum Hypertens 2007; 21: 173-175
    CrossrefPubMedGoogle Scholar
  • 20 Xia K, Ding R, Yang Y. et al. [Association between serum leptin, adiponectin, visfatin, obesity and hypertension in female]. Zhonghua nei ke za zhi 2015; 54: 768-772
    PubMedGoogle Scholar
  • 21 Horbal SR, Seffens W, Davis AR. et al. Associations of apelin, visfatin, and urinary 8-isoprostane with severe hypertension in African Americans: The MH-GRID Study. Am J Hypertens 2016; 29: 814-820
    CrossrefPubMedGoogle Scholar
  • 22 Kocelak P, Olszanecka-Glinianowicz M, Owczarek A. et al. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly – results from the PolSenior substudy. J Am Soc Hypertens 2015; 9: 1-8
    CrossrefPubMedGoogle Scholar
  • 23 Gunes F, Akbal E, Cakir E. et al. Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients. Intern Med 2012; 51: 553-557
    CrossrefPubMedGoogle Scholar
  • 24 Liakos CI, Sanidas EA, Perrea DN. et al. Apelin and visfatin plasma levels in healthy individuals with high normal blood pressure. Am J Hypertens 2016; 29: 549-552
    CrossrefPubMedGoogle Scholar
  • 25 Rotkegel S, Chudek J, Spiechowicz-Zaton U. et al. The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity. Kidney Blood Press Res 2013; 37: 124-131
    CrossrefPubMedGoogle Scholar
  • 26 Andreeva AA. [Dynamics the level of visfatin and markers of immune inflammation in hypertensive patients with abdominal obesity using the combination of antihypertensive therapy]. Georgian Med News 2013; 72-77
    PubMedGoogle Scholar
  • 27 Gu SJ, Xuan HF, Lu M. et al. Admission plasma visfatin level strongly correlates with hematoma growth and early neurologic deterioration in patients with acute spontaneous basal ganglia hemorrhage. Clin Chim Acta 2013; 425: 85-89
    CrossrefPubMedGoogle Scholar
  • 28 Huang Q, Dai WM, Jie YQ. et al. High concentrations of visfatin in the peripheral blood of patients with acute basal ganglia hemorrhage are associated with poor outcome. Peptides 2013; 39: 55-58
    CrossrefPubMedGoogle Scholar
  • 29 Wang JX, Hou Y, Ruan SP. et al. Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage. Peptides 2013; 50: 8-12
    CrossrefPubMedGoogle Scholar
  • 30 Kadoglou NP, Fotiadis G, Lambadiari V. et al. Serum levels of novel adipokines in patients with acute ischemic stroke: Potential contribution to diagnosis and prognosis. Peptides 2014; 57: 12-16
    CrossrefPubMedGoogle Scholar
  • 31 Yin CG, Jiang L, Tang B. et al. Prognostic significance of plasma visfatin levels in patients with ischemic stroke. Peptides 2013; 42: 101-104
    CrossrefPubMedGoogle Scholar
  • 32 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430
    CrossrefPubMedGoogle Scholar
  • 33 Wang P, Xu TY, Guan YF. et al. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370-380
    CrossrefPubMedGoogle Scholar
  • 34 Romacho T, Sanchez-Ferrer CF, Peiro C. Visfatin/Nampt: An adipokine with cardiovascular impact. Mediat Inflam 2013; 2013 946427
    PubMedGoogle Scholar
  • 35 Faraco G, Iadecola C. Hypertension: A harbinger of stroke and dementia. Hypertension 2013; 62: 810-817
    CrossrefPubMedGoogle Scholar
  • 36 Zhao Y, Guan YF, Zhou XM. et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade. Stroke 2015; 46: 1966-1974
    CrossrefPubMedGoogle Scholar
  • 37 Erfani S, Khaksari M, Oryan S. et al. Nampt/PBEF/visfatin exerts neuroprotective effects against ischemia/reperfusion injury via modulation of Bax/Bcl-2 ratio and prevention of caspase-3 activation. J Mol Neuroscience : MN 2015; 56: 237-243
    PubMedGoogle Scholar
  • 38 Takebayashi K, Suetsugu M, Wakabayashi S. et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 451-458
    CrossrefPubMedGoogle Scholar
  • 39 Meier FM, Frommer KW, Peters MA. et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis. J Biol Chem 2012; 287: 28378-28385
    CrossrefPubMedGoogle Scholar
  • 40 Kim SR, Bae YH, Bae SK. et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-kappaB activation in endothelial cells. Biochim Biophys Acta 2008; 1783: 886-895
    PubMedGoogle Scholar
  • 41 Shi KL, Qian JY, Qi L. et al. Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-kappaB activation in HCAECs. Oncol Lett 2016; 12: 1438-1444
    CrossrefPubMedGoogle Scholar
  • 42 Romacho T, Azcutia V, Vazquez-Bella M. et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-2463
    CrossrefPubMedGoogle Scholar
  • 43 Xiao J, Xiao ZJ, Liu ZG. et al. Involvement of dimethylarginine dimethylaminohydrolase-2 in visfatin-enhanced angiogenic function of endothelial cells. Diabetes Metab Res Rev 2009; 25: 242-249
    CrossrefPubMedGoogle Scholar
  • 44 Kong Q, Xia M, Liang R, Li L, Cu X, Sun Z, Hu J. Increased serum visfatin as a risk factor for atherosclerosis in patients with ischaemic cerebrovascular disease. Singapore Med J 2014; 55: 383-387
    CrossrefPubMedGoogle Scholar